PDCD1 and B-cell chronic lymphocytic leukemia: Indeed, PD-1 blockade in patients with B-CLL, either as a single agent therapy or in combination with ibrutinib, has elicited clinical responses [14], although the role of PD-1 on NK cells in patients with B-CLL has not been explored.